close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

26.27 +1.96 (+8.09%)
Delayed Quote Updated: 12:57 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tango Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
The study is evaluating the combination in patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS mutant non-small cell lung cancer 
From Tango Therapeutics, Inc.; Erasca, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET 
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Executive Chair Transition
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Appoints Robert Azelby to Board of Directors
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Proposed $500 Million Public Offering
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Participate in Upcoming Investor Conferences
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Announces Discontinuation of TNG348 Program
From Tango Therapeutics
Via Business Wire
News headline image
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Participate in Upcoming Investor Conferences
From Tango Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.